Welcome Statement by Alfred Maelicke, CEO of Galantos Pharma
GalantosPharma was founded in 2005 with the aim of satisfying the urgent medical need in Alzheimer’s disease (AD) for drugs combining both, efficient cognition enhancement and slowing down of disease progression. Rather than joining the band of companies that tried immunotherapeutic or other approaches aimed at removing excessive or misfolded extracellular ß-amyloid, our program started out from nature-derived compounds, such as the plant alkaloid and marketed AD drug galantamine (Reminyl®, Razadyne®), and aimed at improving crucial properties of these multi-mode leads. Galantos’ most advanced drug candidate Memogain® is a NCE and pro-drug of galantamine that is more hydrophobic than its parent compound and hence partitions much more efficiently into the brain. There it is enzymatically cleaved and releases galantamine at dramatically enhanced bioavailability in the brain. Preclinical development of Memogain® has been completed and the requirements for first-in-human clinical studies have all been fulfilled. Memogain is expected to offer decisive improvements in medical benefit compared to currently available AD drugs. Memogain may produce larger and more sustained cognition enhancement, faster and stronger onset of efficacy, and significant slowing of disease progression. Because it does not cause any significant gastrointestinal side effects, Memogain will neither require slow uptitration of dose (as do all so called cholinesterase inhibitor drugs), nor will dosing be limited by the level of adverse effects tolerated by the individual patient.
In August 2013 GalantosPharma has sold all assets related to Memogain® to the Canadian drug development company Neurodyn Inc. whose focus is on identifying, validating and developing natural bioactives into both prescription drugs and natural products for early treatment of neurological diseases. Neurodyn has taken over clinical development of Memogain not only for mild-to-moderate Alzheimer’s disease but also for Parkinson’s and other neurodegenerative diseases. Neurodyn and GalantosPharma will continue to collaborate, with Alfred Maelicke serving as Neurodyn’sManaging Director Europe.